CF

EQS-News: SGL Carbon's business performance after nine months confirms the announced stabilization and investment year

Retrieved on: 
Tuesday, November 7, 2023
SGL Carbon, EBITDA, Wind, CS, EBIT, LED, Growth, Income tax, GS, PT, I3, Depreciation, Meyn Food Processing Technology, Investment, CF, Advanced Composites Solutions, Silicon, Carbon fibers, Security (finance), Cryptocurrency, Bookkeeping

Accordingly, the adjusted EBITDA of the Group also decreased only slightly by 4.5% to €130.0 million (9M 2022: €136.1 million).

Key Points: 
  • Accordingly, the adjusted EBITDA of the Group also decreased only slightly by 4.5% to €130.0 million (9M 2022: €136.1 million).
  • Overall, sales in the Semiconductor and LED market segment rose by 38.5% to €189.0 million in the first nine months of 2023.
  • Taking into account depreciation and amortisation of €43.3 million, adjusted EBIT (EBITpre) after nine months amounted to €86.7 million (9M 2022:€92.2 million).
  • Further details on business development and outlook can be found in the Group interim statement on the first nine months of 2023.

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 6, 2023
Priority review, Neoplasm, Research, 27th Construction Company (U.S. Army Air Service), Food, Phase 1, ID, KRYS, New Drug Application, Data monitoring committee, Marketing, CGMP, Sale, Netherton syndrome, NCT, Lung, Form, PRV, DEB, IL-12, Immunology, Investment, Patient, Cohort, Financial result, Medicines and Healthcare products Regulatory Agency, Immunotherapy, Clinical trial, Medicaid, AATD, Society, CF, Survival, FDA, IND, Genotype, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inhalation, ASTRA, Pharmaceutical industry, Vaccine, Clothing, Bookkeeping, Rolling (metalworking), Reinsurance, Security (finance), Cryptocurrency, EU

Financial results for the quarter ended September 30, 2023:

Key Points: 
  • Financial results for the quarter ended September 30, 2023:
    Cash, cash equivalents, and investments totaled $598.6 million on September 30, 2023.
  • For additional information on the Company’s financial results for the quarter ended September 30, 2023, please refer to the Form 10-Q filed with the SEC.
  • For additional information on the Company’s financial results for the nine months ended September 30, 2023, please refer to the Form 10-Q filed with the SEC.
  • Krystal Biotech will host a conference call to discuss its third quarter 2023 financial results and business highlights today, November 6, 2023, at 8:30 a.m.

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Saturday, November 4, 2023
Survival, UCB, NAM, Immune reconstitution inflammatory syndrome, Therapy, CD57, MD, Infection, Cell, SITC, Immunotherapy, B cell, Science, NF, Immunophenotyping, Annual general meeting, Kinetics, Culture, Society, Cancer, Patient, CF, Non-Hodgkin lymphoma, Fibroblast, Myelocyte, Pharmaceutical industry, Vaccine, NK

(Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today shared new data on the impact of the company’s proprietary nicotinamide (NAM) technology on its allogeneic stem cell therapy omidubicel and investigational natural killer (NK) cell therapy candidate GDA-201 at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in San Diego, CA.

Key Points: 
  • (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today shared new data on the impact of the company’s proprietary nicotinamide (NAM) technology on its allogeneic stem cell therapy omidubicel and investigational natural killer (NK) cell therapy candidate GDA-201 at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in San Diego, CA.
  • Both omidubicel and GDA-201 are powered by Gamida Cell’s proprietary NAM technology, which enhances and expands cells to create potentially curative cell therapies for patients with cancer.
  • Omidubicel was approved under the brand name Omisirge™ (omidubicel-onlv) by the U.S. FDA in April 2023 for allogeneic stem cell transplant; GDA-201 is in Phase 1 study for the treatment of non-Hodgkin lymphoma (NCT05296525).
  • Data on the first three cohorts of the Phase 1 study of GDA-201 were recently reported.

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

Retrieved on: 
Friday, October 27, 2023
NYSE, Psoriatic arthritis, Conference, Cystic fibrosis, Congress, Part, NESS, CF, Pharmaceutical industry

The abstract was selected for an oral presentation at the conference.

Key Points: 
  • The abstract was selected for an oral presentation at the conference.
  • The Phase 1b/2a data for BX004 will also be available as an e-poster on the virtual congress platform.
  • Details of the oral presentation are as follows:
    Session Name: W22-What’s New in Clinical Trials in CF?
  • The poster will also be made available on the publications section of the BiomX website on November 3, 2023.

Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference

Retrieved on: 
Thursday, November 2, 2023
Health, Consumer, Children, Clinical Trials, Pharmaceutical, Biotechnology, Medical Affairs Bureau, Vertex, VRTX, Life, Vertex Pharmaceuticals, Conference, Elexacaftor/tezacaftor/ivacaftor, Cystic fibrosis transmembrane conductance regulator, Poster, Disease, Cystic fibrosis, CF, Pharmaceutical industry, Dietary supplement, CFTR

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat the underlying cause of cystic fibrosis (CF) in ~90% of people with the disease, will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) taking place November 2-4, 2023 in Phoenix, Arizona.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat the underlying cause of cystic fibrosis (CF) in ~90% of people with the disease, will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) taking place November 2-4, 2023 in Phoenix, Arizona.
  • Presentations will highlight results from two open-label extension studies demonstrating the long-term clinical benefits and safety profile of TRIKAFTA® among CF pediatric populations.
  • Vertex will present interim data on TRIKAFTA® from its longest pediatric follow-up study to date.
  • The data also showed a continued favorable safety profile, with no new safety findings (Poster #133).

Cadillac Fairview sparks holiday magic and togetherness, inviting guests to experience 'CF Winterville' at shopping centres across Canada this season

Retrieved on: 
Wednesday, November 1, 2023
Markville Shopping Centre, Spectrum, Holiday, Barenaked Ladies, Toronto Children's Chorus, Fairview Park Mall, Live Music, Hope, Family, Chinook Centre, Lady Luck, Eaton Centre, Friends, Toronto Eaton Centre, Covenant House, Polo Park, Organic, Risk, Magic, Partnership, Lime Ridge Mall, Snow, Cadillac Fairview, CF, Sherway Gardens, Marketing, Tourism, Hospitality industry, Mail order, Amusement park, Nightclub

CF Sherway Gardens Holiday Market: Beginning Nov. 23

Key Points: 
  • CF Sherway Gardens Holiday Market: Beginning Nov. 23
    CF Sherway Gardens is delighted to invite guests to discover a month-long Holiday Market starting on November 23.
  • The market will feature more than 25 local vendors from Québec, making the centre the perfect one-stop destination for holiday gift shopping.
  • Tree-lighting ceremonies will continue this season featuring musical performances and special guests, including the jolly man in red himself.
  • To learn more about CF's holiday hours, experiences and services, along with event registration and ticketing info, please visit https://shops.cadillacfairview.com/holiday

Moligo Technologies and Nationwide Children's Hospital Collaborate to Advance Cystic Fibrosis Research Using Ultrapure Long Single-Stranded DNA

Retrieved on: 
Tuesday, October 24, 2023
Sequence, Sale, DNA, AAV, Vaidyanathan, CFTR, Research, Reactive airway disease, Risk, Crownsville Hospital Center, Gene, Cystic fibrosis, Nationwide Children's Hospital, Patient, Hospital, CF, B cell, Cystic fibrosis transmembrane conductance regulator, Vaccine

STOCKHOLM, Oct. 24, 2023 /PRNewswire/ -- Moligo Technologies announced today that it has signed a collaboration agreement with Nationwide Children's Hospital to provide long, single-stranded DNA for its research into gene therapies for cystic fibrosis (CF) and other airway diseases. Moligo's patent-pending enzymatic DNA production technology delivers ultrapure, long ssDDNA at industrial sale - with the ability to introduce chemical modifications - making it potentially suited as a non-viral delivery method in cell and gene therapies.

Key Points: 
  • STOCKHOLM, Oct. 24, 2023 /PRNewswire/ -- Moligo Technologies announced today that it has signed a collaboration agreement with Nationwide Children's Hospital to provide long, single-stranded DNA for its research into gene therapies for cystic fibrosis (CF) and other airway diseases.
  • While significant advances have been made in gene therapy, using the approach for airway diseases is still in the early stages.
  • Moligo utilizes a proprietary, PCR-free, enzymatic technology to produce ultrapure DNA strands over 10,000 bases long, 100 percent sequence-verified, and at scale.
  • Sequence complexity is also a significant challenge, making encoding many complete and functional long therapeutic genes into ssDNA impossible.

Dalmore Group to Sponsor CFA LA Annual Portfolio Conference Alongside Blackrock, Invesco And More

Retrieved on: 
Thursday, October 19, 2023
Omni, Invesco, Butler, Investment Week, Landa, Conference, Dalmore, Reg Plummer (field hockey), Black Rock, CF, State Street

LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Dalmore Group , the leading broker-dealer for Reg A and CF financing, will sponsor and speak at the 2023 annual Portfolio Conference hosted by the CFA Society of Los Angeles.

Key Points: 
  • LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Dalmore Group , the leading broker-dealer for Reg A and CF financing, will sponsor and speak at the 2023 annual Portfolio Conference hosted by the CFA Society of Los Angeles.
  • As one of the West Coast's most prominent conferences for institutional investors, the summit will also bring together sponsors including Blackrock, Invesco, State Street, Principal Asset Management and more.
  • Dalmore Group Chairman Etan Butler will take the stage for a panel alongside North Capital, Shinnecock Partners and Landa to discuss fractionalization of high value assets.
  • "Dalmore has brought order to that market by providing the technology and strategy to bridge the gap between issuers, institutions and investors."

Susan A. Ellerbusch Elected to Board of Directors of CF Industries Holdings, Inc.

Retrieved on: 
Tuesday, October 17, 2023
Agriculture, Natural Resources, Sustainability, Environment, Alternative Energy, Energy, Chemicals, Plastics, Manufacturing, Annual general meeting, Air Liquide, Human, NYSE, Hydrogen, BP, CF Industries, CF, Management

CF Industries Holdings, Inc. (NYSE: CF) today announced that its Board of Directors has elected Susan A. Ellerbusch, a global leader in chemicals and energy industries, as an independent director of the company.

Key Points: 
  • CF Industries Holdings, Inc. (NYSE: CF) today announced that its Board of Directors has elected Susan A. Ellerbusch, a global leader in chemicals and energy industries, as an independent director of the company.
  • Ms. Ellerbusch has served in a series of diverse leadership roles at Air Liquide since 2015, including as chief executive officer, Air Liquide North America, LLC.
  • The election of Ms. Ellerbusch brings membership of the CF Industries Holdings, Inc. Board of Directors to twelve.
  • We look forward to her contributions as we work together to create long-term value for our shareholders.”

CF Industries Holdings, Inc. Declares Quarterly Dividend and Confirms Dates for First Nine Months and Third Quarter 2023 Results and Conference Call

Retrieved on: 
Tuesday, October 17, 2023
Environment, Other Energy, Chemicals, Plastics, Manufacturing, Sustainability, Energy, Other Natural Resources, Agriculture, Natural Resources, NYSE, Webcast, CF Industries, CF

CF Industries Holdings, Inc. (NYSE: CF) today reported that its board of directors has declared a $0.40 per share dividend on its common stock.

Key Points: 
  • CF Industries Holdings, Inc. (NYSE: CF) today reported that its board of directors has declared a $0.40 per share dividend on its common stock.
  • The dividend will be payable on November 30, 2023, to stockholders of record as of November 15, 2023.
  • Additionally, the Company confirmed that it will report its first nine months and third quarter 2023 results after the market close on Wednesday, November 1, 2023.
  • Investors can access the call by dialing 833-634-5017 (toll-free) or 412-902-4213 (international) and ask to be joined into the CF Industries call.